DataSheet2_Satisfaction With Governmental Risk Communication Both Increases and Decreases COVID-19 Mitigation Behaviours.docx by Darrick Evensen (13757068)

“…</p><p>Methods:Via a survey (N = 4,206) of representative samples of the general public in five European countries (Germany, Norway, Sweden, Switzerland, United Kingdom), we explore perceptions of a range of personal/public health, economic, and societal risks. …”

Fig6B_modifiedSplitter_adjustTidalVolume_Patients_C_C_decrease: Variables for pair C-C, where the Tidal Volume of one patient was decreased by 30% whilst maintaining the other patient constant. from A simulated single ventilator/dual patient ventilation strategy for acute respiratory distress syndrome during the COVID-19 pandemic by José A. Solís-Lemus (9272948)

TSLPR deficient mice show decreased AHR upon HDM exposure. by Latifa Koussih (326043)

Placental aromatase expression decreased in severe neonatal opioid withdrawal syndrome by Courtney Townsel (6705368)

rHSP60 decreases LPS-induced mononuclear cell proliferation. by Igor Emiliano L. Souza (18196495)

Decreased vagal activity and deviation in sympathetic activity precedes development of diabetes by Da Young Lee (8617365)

Infectiousness profiles of SARS-CoV-1 and SARS-CoV-2. by Matteo Serafino (11599593)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: